Publication for MS4A1 and CD79B

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MS4A1	membrane spanning 4-domains A1	931			[link]
hsa	CD79B	CD79b molecule	974

Pubmed ID	Priority	Text
25629549	0.98	CD79B, FCER2, and MS4A1; Figure 4d).
	0.96	CD79B, FCER2, FCRL2, ID3, IGKC, IGLL1, MS4A1, MZB1 and TCL1A) belonging to the top-ranked gene lists (Supplementary Figure SI5 online) from the different studies.
28009435	0.97	CD20+ B cells (panels A and B) or CD3+ T-cells (panels C and D) in animals administered either anti-CD22 (panels A and C) or anti-CD79b (panels B and D) ADCs (n = 4); respective unconjugated antibodies (Ab) (n = 4) or vehicle (n = 4) over time are presented.
	0.96	CD20+ B cells following administration of anti-CD22 or anti-CD79b ADCs in ADC studies
	0.94	CD20+ B cells following administration of anti-CD22 or anti-CD79b ADCs.
28085915	0.97	CD79B and MS4A1 were increased in stable and rejection-free patients but decreased at the time of acute rejection, respectively.
	0.92	CD79B, FCRL1, FCRL2, MS4A1, TCL1A), cytokine receptors CCR5 and CCR7, CD200, the transcription factor IRF5, the toll-like receptor TLR5, HS3ST1 (heparan sulfate 3-O-sulfotransferase 1), and SH2D1B, a gene playing a role in signal transduction of antigen-presenting cells in the TAC-group (Fig 7).
21617698	0.97	CD20; B. CD5 by CD23; C. CD5 by sIg, D. CD5 by CD49d, E. CD5 by CD79b, F. CD5 by FMC7, G. IgD by IgM. To characterize the B cell maturation state of different MBL subtypes, plots of IgD by CD38 (H) and IgD by CD27 (I) were displayed.
28119695	0.97	CD79B, TCL1A, SH2D1B, MS4A1, FCRL1, and FCRL2) that were associated with B cell-related pathways.
32153573	0.95	CD20, CD21, CD22, CD23, CD24, CD27, CD37 to CD39, CD40, CD72 to CD78, CD79a, CD79b, CD80 to CD86, CD138, CD139, CD179a, CD179b, CD180, CD252, CD254, CD267 to CD269, CD275, CD307e, CD315 to CD317, CD307a to CD307d, and CD351 to CD363.
32138770	0.89	CD79B, and MS4A1 for B cells; CD3E and CD3D for T cells;
	0.77	CD79B, and MS4A1 were only detected in 9.09% of T cells sorted on CD8A or CD4 (Fig. 4a,b).
25853860	0.84	CD20-, CD22-, CD23-, CD25-, CD27-, CD40-, CD52-, CD56-, CD79b- and FMC7- (Fig 1).
27479184	0.72	CD20, CD79b, VPREB3, TNFSF8 and CCND1 as revealed by comparing their GEP against that of PCs obtained from patients with intermediate- (CD19-CD81+) and fully differentiated phenotypes (CD19-CD81-).
29024461	0.68	CD20, and CD79b are characteristically low compared with those found on normal B cells.
30348985	0.65	MS4A1 (protein alias CD20), CD22, CD52 without expression of either CD27 or CD138 which suggest that this cluster is comprised of mature antigen inexperienced B cells (top DE genes: MS4A1, LTB, CD37, CD79B, CD52, HLA-DQB1, TNFRSF13C, TCL1A, LINC00926, STAG3, IGHD, BANK1, IRF8, BIRC3, P2RX5, RP11-693J15.5, RP5-887A10.1, VPREB3, CD22, CD74, SELL).
25259521	0.61	CD20, CD71, CD79b).
27328267	0.60	CD79b, TCL1A, SH2DB1, FCRL1, and MS4A1), further strengthening the argument that the expression of genes included in the IoT signature was influenced by IS drug regimens.
32245446	0.53	MS4A1, CD79A, CD79B), as well as a number of immune checkpoint pathway genes (CD28, CD80, CD86, CD274 (PD-L1), PDCD1LG2 (PD-L2), PDCD1 (PD1), ICOSLG, ICOS, CD274 and LAG3) (Supp.